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Abstract: Skeletal muscle formation is a multi-step process that is governed by complex networks
of transcription factors. The regulation of their functions is in turn multifaceted, including several
mechanisms, among them alternative splicing (AS) plays a primary role. On the other hand, altered AS
has a role in the pathogenesis of numerous muscular pathologies. Despite these premises, the causal
role played by the altered splicing pattern of transcripts encoding myogenic transcription factors
in neuromuscular diseases has been neglected so far. In this review, we systematically investigate
what has been described about the AS patterns of transcription factors both in the physiology of the
skeletal muscle formation process and in neuromuscular diseases, in the hope that this may be useful
in re-evaluating the potential role of altered splicing of transcription factors in such diseases.
Keywords: skeletal muscle; alternative splicing; transcription factor; differentiation; myogenesis;
neuromuscular disease
1. Introduction
Skeletal muscle formation (myogenesis) is a multi-step process that is tightly regulated by a
complex network of muscle specific and ubiquitous transcription factors (TFs). Specific combinations
of TFs dictate the correct spatial and temporal expression of gene expression programs underlying
all aspects of skeletal muscle development and post-natal muscle growth. In adult life, they also play
key roles in adult skeletal muscle regeneration, muscle mass homeostasis and myofiber plasticity in
response to specific functional needs and nutritional conditions. Developmental and adult myogenesis
are controlled by external signaling molecules (morphogens) that activate signaling pathways
ultimately converging on the function of nuclear TFs and chromatin remodeling complexes [1]. Hence,
the activities of TFs must be highly and coordinately regulated during the various waves of muscle
differentiation during all life of metazoans. The functions of TFs are modulated by several molecular
and biochemical mechanisms including gene transcriptional regulation, alternative splicing (AS) of
pre-mRNA, protein translation, post-translational modifications and controlled protein stability. AS is
widespread in eukaryotes and several studies, including genome-wide analysis, have demonstrated
that AS has a great impact on the regulation of TFs activities, allowing a finer and more articulated
modulation in respect to that of all or nothing that may result from the regulation of their gene
expression [2–4]. In general, splice variants result in proteins with different functions. These can range
from minimal changes in function to absolutely opposite functions. Given the modular structure of TFs,
the biological effects of AS on the activity of TFs is often straightforwardly predictable. For example,
AS can change the DNA-binding properties, introduce or eliminate activating domains or domains
involved in their interaction with coactivators. Furthermore, it can increase the in vivo stability of a
given isoform. TFs isoforms can have stage-specific and tissue-specific expression patterns throughout
the development of an organism, suggesting that individual isoforms may serve specific spatial or
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temporal roles. These splicing patterns are regulated in a temporal and cell-specific manner by the
expression of specialized pre-mRNA binding proteins (RBPs) [5]. Several myogenic TFs are subjected
to complex patterns of AS and the functional consequences on their activities in muscle cells have
been described. AS is involved in the regulation of normal physiological functions as well as in
pathologies and several neuromuscular diseases are characterized by aberrant AS [6–9]. For example,
Myotonic Dystrophy type 1 and 2 (DM1 and DM2) and facioscapulohumeral muscular dystrophy
(FSHD), the most common adult onset muscular dystrophies, are characterized by wide alterations of
AS of muscle genes involved in muscle function. Many of the mis-regulated splicing events directly
correlate with several clinical features of the pathologies, however it has been reported that in these
pathologies there are also important alterations of gene expression, in principle these might be caused
by misregulation of AS of TFs, an aspect that has so far remained elusive. To start exploring this issue,
in this review, we have summarized the physiological and pathological significance of AS events in
regulating the activities of TFs in skeletal myogenesis and in neuromuscular diseases. Our studies
show that a large proportion of ubiquitous TFs involved in myogenic transcription are regulated by AS
of their transcripts and for many of them aberrant AS has been observed in neuromuscular pathologies.
These observations suggest that their altered activities could play an important pathogenic role in
these diseases and therefore correcting their AS might represent a valuable therapeutic strategy.
2. Myogenesis
Skeletal myogenesis is a process that takes place in several sequential steps involving the
determination of founder stem cells to become committed proliferating myoblasts, which terminally
differentiate to myocytes and, in turn, fuse to give multinucleated myotubes. Ultimately, as a result of
maturation processes, myotubes become structurally organized in contractile myofibers [10,11].
2.1. Myogenesis During Embryonic Development
Muscles of the trunk, the limbs the tongue and some of the neck muscles of vertebrates originate
from the somites, which are metameric epithelial structures derived from the segmentation of paraxial
mesoderm on both side of the neural tube; they start to appear at embryonic day E8 in the mouse [12].
Soon after their formation, somites differentiate in a ventral mesenchymal region, the sclerotome that
contains the precursors of bone and cartilage of the ribs and the vertebrate column, while the dorsal
part of the somite, the dermomyotome, contains the precursors of the future skeletal muscles, as well
as the derm of the back, the brown fat, smooth muscles and endothelia [11,13,14]. Muscles of the back
originate from muscle progenitors that are located in the epaxial part of the dermomyotome, near the
neural tube, whereas the hypaxial dermomyotome gives rise to the muscles of the body wall. During
development of most mammals, skeletal muscle formation occurs in three consecutive, although
partially intersecting, waves [11,15–17]. A first wave of myogenesis involves a population of muscle
precursors, that are marked by the Myf5 (Myogenic Factor 5) myogenic determinant and are located in
the epaxial and hypaxial lips of the dermomyotome, and give rise to the skeletal primary myotome (at
embryonic day E8.75 in the mouse). Skeletal myotome is constituted by mononucleated muscle cells
(myocytes) that are elongated along the axis of the somite. Once myotome is established, embryonic
muscle growth is ensured in successive steps involving distinct populations of myoblasts. During
E10–E12 in the mouse and Weeks 8–10 of human gestation, embryonic myoblasts differentiate into
multinucleated myotubes called primary myofibers (primary myogenesis), which act as scaffolding
for secondary (fetal) fibers that form between E14.5 and E17.5 in the mouse and between gestational
Weeks 10 and 18 in humans [18]. Embryonal and fetal myogenesis are dependent on founder stem cells,
originating from the central part of the dermomyotome, that are marked by the paired box transcription
factors PAX3/PAX7. Skeletal muscles of the diaphragm and limbs originate from migrating PAX3
positive cells, that delaminate from the ventro-lateral lip of the dermomyotome in the cervical or limb
level somites. Their migration is dependent on the expression of the Hepatocyte Growth Factor (HGF)
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receptor c-Met [19]. Some of the head muscles are derived from cranial paraxial mesoderm and from
prechordal mesoderm.
2.2. Post-Natal Myogenesis
After birth, skeletal myofibers that were formed during development undergo massive growth
and fiber type specialization to become mature myofibers that can respond to the metabolic needs and
complex movements of an adult organism. The de novo fiber formation (hyperplasia) ends by birth or
shortly afterward. From the neonatal period, skeletal muscles continue to grow almost exclusively by
increasing the myofiber size (hypertrophy). The new myonuclei are supplied by the progeny of muscle
satellite cells (SC), a population of muscle progenitors that emerges at the end of the fetal myogenesis
(E16.5 in the mouse) and which are identified by the expression of the paired box transcription factor
PAX7 and by their location beneath the basal lamina (SC niche) [20,21]. At the end of muscle growth
(P21 in the mouse), most SCs become mitotically quiescent in adult muscle. Beyond this point until
adulthood, the volume of myofibers increases by protein accretion [22,23]. Quiescent SCs represent
muscle resident stem cells, indeed, they can re-enter the cell cycle upon activation in response to several
stimuli, ranging from intense exercise, muscle damage or physiological muscle turn-over. SC-derived
myoblasts proliferate and terminally differentiate to repair muscle, while a proportion of activated SCs
return to quiescence to repopulate the SC pool [24]. Several contractile proteins undergo a transition
from neonatal to adult splice isoforms in the first three weeks of life in the mice [25].
Another important aspect in skeletal muscle maturation is the establishment of fiber type
composition. In vertebrates, adult skeletal muscle is composed of variable proportions of heterogeneous
specialized myofibers that differ in size, shape, metabolic and contractile properties to fulfill the
different functional needs of the body, such as maintaining body posture, perform a wide range of
movements and control global body metabolism. Adult mammalian skeletal myofibers are classified
based on their speed of contraction, which is related to the ATPase function of the main Myosin
Heavy Chain (MyHC) isoform. Slow-twitch fibers (type 1, red muscle) produce lower forces and their
metabolism is mainly oxidative, whereas fast-twitch fibers (type 2, white muscle) can produce higher
forces than slow ones, and they are glycolytic and less fatigue resistant [26]. Besides MyHCs, the
fast-twitch and slow-twitch fibers express different isoforms and/or different quantities of the majority
of myofibrillar proteins and of several additional genes [27,28]. The typical fiber-type composition
of each muscle is established during development, however in mammals it is subject to extensive
plasticity in response to changes in metabolic and functional requirements, displaying changes in fiber
size (e.g., muscle hypertrophy) and type (e.g., fast-to-slow fiber type switch) [26,29].
3. Transcriptional Control of Skeletal Myogenesis
All aspects of skeletal myogenesis are under the control of transcription regulators. They form
distinct gene regulatory networks that orchestrate the ordered spatio-temporal expression of
muscle-specific genes. The families of TFs that regulate postnatal myogenesis are the same that
also control skeletal myogenesis during early development [30,31]. The networks of TFs controlling
skeletal myogenesis are depicted in Figure 1.
3.1. Families of Myogenic Transcription Factors
3.1.1. PAX3 and PAX7
The transcriptional cascades that control muscle genes is governed by the paired-homeobox TFs
PAX3 and PAX7 [11,14,32]. During development PAX3 is expressed in the dermomyotome, where
it functions as a muscle cell fate determinant. In addition, it promotes muscle progenitor survival
and regulates the balance between self-renewal and muscle differentiation [11,16,33–35]. PAX3 is also
important for limb myogenesis, by controlling the expression of c-Met, the tyrosine kinase receptor of
HGF, which plays a key role in the migration of muscle progenitors to the limb buds [11,16]. During
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fetal myogenesis, PAX3 expression decreases and muscle progenitors express the PAX7 paralogue
from mid-embryogenesis throughout adulthood. PAX3 and PAX7 control the beginning of muscle
differentiation by promoting, directly or indirectly, the expression of muscle regulatory factors (MRFs)
of the myogenic determination factor (MyoD) family [36,37]. The expression of MRFs in the head
muscle progenitors is not activated by PAX3 but is downstream to transcriptional networks that
are initiated by the bicoid-related Paired Like Homeodomain 2 (PITX2) TF and the T-box factor
TBX1 [38–42]. A role for mesenchyme homeobox gene 2 (MEOX2) has been proposed in the regulation
of the Myf5 gene together with PAX3, at least in vitro [43].
3.1.2. SIX1 and SIX4
SIX1 and SIX4 TFs belong to the sine oculis homeobox homolog family; together with their
co-activators Eyes Absent (EYA), they have been pointed out as transcriptional activators of Myf5 in
the limb and hypaxial somite, synergistically with PAX3, in addition they function as direct activators
of Myogenic Differentiation (MyoD) gene [37,44–47]. Besides, having a role in the early phase of skeletal
myogenesis, SIX proteins are also important activators of myogenin and muscle genes expression during
muscle terminal differentiation. Post-natally, they play a role in the differentiation of slow-twitch or
fast-twitch muscle fibers, as discussed below.
3.1.3. Myogenic Regulatory Factors
The MRFs include MYOD, the first member of the family to be isolated, MYF5, Muscle-Specific
Regulatory Factor 4 (MRF4) and myogenin, they are muscle-restricted class II basic Helix Loop Helix
(bHLH) TFs that direct myogenic differentiation of muscle progenitors of all embryological origins.
MRFs are considered master regulators of myogenic commitment and differentiation due to their
ability to convert several non-muscle cells to the myogenic lineage [48,49]. All MRFs share about 80%
homology within the bHLH domain. The HLH motif serves as an interface for heterodimerization
with ubiquitous HLH proteins of the E-protein class, which include the E proteins HEB/TCF12/HTF4,
E2-2/TCF4/ITF-2 and E12/E47. The basic domain recognizes the nucleotide consensus sequence
CANNTG, known as E-box, that is present in the control regions of most skeletal muscle-specific
genes. All four myogenic bHLH proteins contain a transcription activation domain in their amino and
carboxyl termini, that is important for efficient activation of muscle-specific transcription. In addition,
two other conserved motifs have been identified: a histidine/cystein (H/C) rich domain and a helix
domain (helix III) in the carboxy terminal region [50,51]. The ability of MRFs to activate muscle specific
genes is linked to the presence of three residues (ATK, Alanine- Threonine- Lysine) in their basic
region, differently from other bHLH proteins. This domain is called myogenic “code” and is probably
involved in the interaction with co-regulators. Members of the MyoD family exhibit distinct patterns
of expression in vivo. Genetic deletion experiments in mice have shown that MRFs have only partially
redundant roles during myogenesis: MYF5 and MYOD behave as pioneer myogenic determinants and
MYOD is also important for terminal differentiation of skeletal myoblasts. Myogenin is necessary for
terminal differentiation of all muscle cells; MRF4 plays a role both in early development as well as
in adult muscle [52]. The sequences of H/C and helix III regions are important to confer to MYOD
and MYF5 proteins the ability to initiate chromatin remodeling at the genomic loci of transcriptionally
repressed genes, including myogenin during myogenesis, a property that is mediated by the interaction
with the resident PBX/MEIS heterodimer bound to a MEF3 site. MYOD also recruits to muscle
gene promoters the non-catalytic BAF60C subunit of the SWI/SNF complex. Phosphorylation of
BAF60C by P38 then engages on the promoters the ATPase subunits of the SWI/SNF complex that
can remodel nucleosomes. MYOD is also able to recruit p300/ CREB-binding protein (CBP) and/or
P300/CBP-associated factor (PCAF) on target promoters, where they acetylate the lateral chains of
lysines of the histones H3 and H4 tails and MYOD as well [53–55].
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3.1.4. Repressors of MRFs
The activities of MRFs are negatively regulated by a series of myogenic antagonists that are
themselves HLH domain proteins, such as Inhibitor of Differentiation (ID) proteins (ID1-4), TWIST,
MYOR and MIST-1 [56]. ID comprises a family of HLH proteins that are highly expressed under
high-serum conditions. Their inhibitory activity is based on their ability to heterodimerize with E
proteins, sequestering them and preventing their interaction with the MRFs. TWIST is also a HLH
protein which hampers MRFs ability to activate myogenic gene expression by dimerizating and
sequestering E proteins. TWIST protein inhibits MRFs-dependent transcription also by impeding
the association of MRFs to their E box sequences and by interacting with co-regulators such as
MEF2 proteins.
3.1.5. Co-Activators of MRFs
E-boxes are present in the control regions of most skeletal muscle genes; they are usually flanked
by binding sites for ubiquitous TFs that induce muscle transcription cooperatively with the MRFs.
Some of the ubiquitous factors that cooperate with MRFs in activating muscle genes are themselves
under the control of MRFs, and are therefore involved in the feedforward mechanisms that allow MRFs
to activate early myogenic genes (i.e., myogenin and Mef2d) without delay, whereas late genes (i.e., Mck)
are activated by both MRFs and one or more earlier MRF targets. This feedforward mechanism has
been proposed to explain the temporal control of muscle specific genes by MYOD [57–59]. Thus, MRFs
form protein complexes whose composition determine the timing of expression of muscle-specific
genes. Early expression of the myogenin promoter involves the cooperation of MEF2, PBX/MEIS and
MYOD and the activation of the α-cardiac actin gene promoter is dependent on the interaction between
MYOD, serum response factor (SRF) and SP1 [54,60,61]. The Muscle Creatine Kinase (MCK) gene is
considered a late marker of terminal differentiation and its expression is regulated by an enhancer
that contains binding sites for the myogenic HLH proteins, the Myocyte Enhancer Factor-2 (MEF2)
transcription factor and the mesoderm-restricted homeodomain protein MHOX [62].
3.1.6. Myocyte Enhancer Factor-2 Proteins
The MEF2 family of proteins occupies a leading role among the ubiquitous co-activators of
MRFs [63]. Four members of this family, MEF2A-D, have been identified in the vertebrates to
date [64,65]. Mutational studies in Drosophila, where there is a single Mef2 gene have shown that Mef2
is essential for myogenesis [66–68]. In mammals, MEF2 family members are widely expressed, they
are particularly abundant in precursors of the three muscle lineages and in neurons with overlapping
but distinct temporo-spatial patterns. In somites and limb buds their expression is detected very early,
suggesting an important role of these TFs early in development [69]. Genetic studies in mice and
zebrafish have shown that among the MEF2 factors, MEF2C plays non redundant roles with other MEF2
proteins in late phases of myogenesis, where it is essential in myofiber maturation and sarcomere gene
expression [70,71]. The role of MEF2 proteins is to activate muscle-specific genes in synergy with the
MRFs by forming protein complexes that bind to the regulatory regions of muscle genes. In addition,
MEF2 and MRFs cross-regulate their gene expression. Besides their general role as coactivators of
muscle genes during terminal differentiation, MEF2 proteins play key roles in every aspects of skeletal
myogenesis: they cooperate with Nuclear Factor I/X (NFIX) to promote the fetal/postnatal-specific
gene expression program and they are involved in muscle plasticity and glucose uptake in adult
muscle [30,72–76]. The activity of MEF2 factors is highly regulated by multiple mechanisms, including
post-translational modifications and protein-protein interactions with co-activators and co-repressors.
One well characterized class of MEF2 co-repressors is represented by class II Histone Deacetylases
(HDACs); they interact with MEF2 proteins and recruit to the promoters of muscle genes a multiprotein
repressive complex, including class I HDACs, that keeps MEF2-dependent transcription silent during
the proliferation of muscle precursors [77,78].
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3.2. Transcriptional Control of Specific Gene Expression Programs in Skeletal Muscle
3.2.1. Fetal Specific Gene Expression
Embryonic and fetal myofibers are distinguished based on their contractile and metabolic
properties that are well suited to the needs of the embryo at the two developmental stages. The different
properties are conferred by a distinct pattern of gene expression that has been determined [15].
The transcription factor SOX6, a member of the Sry-related HMG box (Sox) factor family, is expressed
in embryonic myoblasts, where it activates the transcriptional activity of MEF2C, thus promoting
the expression of Myh7, encoding the slow muscle isoform of Myosin Heavy Chain (MyHC I) [79].
The transition of skeletal muscle from the embryonic to the fetal/post-natal phenotype requires a
transcriptional switch, where a paramount role is played by NFIX protein and MEF2 TFs. NFIX
represses embryonic gene expression by recruiting SOX6 to the promoters of embryonic genes, it
activates fetal myogenic genes, such as MCK or β-enolase, by forming a complex with Protein Kinase C
θ (PKC θ) that in turn binds, phosphorylates and activates MEF2A [73,79].
3.2.2. Muscle Plasticity
Subdivision into distinct muscle fiber types is established during fetal development in mice when
the fetal myogenic program is activated and is followed by fiber-type specification that is governed
by SIX1 and SIX4, which promote the fast fiber fate, together with the transcriptional repressor
SOX6, which represses slow genes in fast fibers [80,81]. Postnatally, upon neuronal innervation,
there is a substantial change in muscle fiber-type distribution. This adaptive capacity is maintained
throughout adult life and it occurs chiefly at the transcriptional level. For example, long trains of
low frequency impulses from the slow motor units induce the slow fiber phenotype leading to a
sustained increase of intracellular calcium that activates both the calcium calmodulin-dependent
protein kinase IV (CaMKIV) and the calmodulin-dependent protein phosphatase calcineurin A (CnA).
CaMKIV catalyzes the phosphorylation of class II Histone Deacetylases HDAC4 and HDAC5, which
thus translocate out of the nucleus and allow MEF2 TFs to interact with coactivators, including
CBP/P300 and proliferator-activated receptor gamma coactivator 1α (PGC-1α) [82]. In addition,
elevated intracellular calcium activates CnA that in turn triggers nuclear translocation and activity of
calcium-dependent nuclear factor of activated T cells (NFATc) [83,84], as well as the function of MEF2
TFs [85]. Calcium signaling activates also the peroxisome proliferator activated receptor δ (PPARδ)
and its coactivator PGC-1α, that synergistically activate slow muscle genes [30,86–88]. Myogenin and
MYOD have been shown to play a role as well in promoting respectively the slow and fast-specific
gene expression programs in mature myofibers [85,89,90].
3.2.3. Muscle Mass Homeostasis
In the adult, muscle mass is regulated by a balance between protein synthesis and degradation in
response to nutritional and activity signals. Several pathologic states, including cancer or disorders
that disrupt neuronal supply to the muscle, such as amyotrophic lateral sclerosis (ALS), result in loss of
muscle mass, referred as muscle atrophy, characterized by an excess of ubiquitin-mediated proteolysis.
Various TFs are involved in the control of metabolic genes, among which forkhead box FOXO1
and FOXO3A proteins, whose activity is regulated mainly through the AKT Serine/Threonine Kinase
signaling pathway [91,92]. Genes under the transcriptional control of FOXOs include catabolic,
autophagy-related and atrophy-related genes (atrogenes), such as atrogin 1 (also known as MAFbx)
and MuRF, encoding ubiquitin ligases, Microtubule Associated Protein 1 Light Chain 3 Alpha, encoding
the Autophagy-Related Protein LC3, SQSTM1 and NBR1 [92–94]. FOXOs-regulated catabolic genes
and atrogenes are controlled also by nuclear factor-κB (NF-kB) and myogenin in synergy with class II
histone deacetylases HDAC4 and 5 [95]. Altogether, these TFs give rise to a coordinated transcriptional
program and cooperate with other pleiotropic TFs, such as Serum Response Factor (SRF) and the
Activator Protein 1 transcription factor subunit JUNB [96–98]. Recent work has implicated MEF2
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factors as inducer of muscle growth, their pro-hypertrophic activities is under the negative control of
MRF4 [75].Genes 2018, 9, 107  7 of 31 
 
 
Figure 1. Model of skeletal muscle formation and the transcription factors (TFs) involved in the 
control of the different waves of myogenesis. MYF5+ cells from the somitic dermomyotome are the 
first muscle precursors that differentiate into the myocytes of the early myotome, which provides the 
basic scaffold on which skeletal muscle forms in the sequential waves of myogenesis. Subsequently, 
PAX3/PAX7 positive cells give rise to muscle precursors during development and post-natal muscle 
growth: embryonic and fetal myoblasts give rise to embryonic and fetal myofibers, respectively. 
Satellite cells (SC) appear at the end of gestation and are responsible for postnatal growth (juvenile 
SC) and regeneration (adult SC). Extraocular and first branchial arch-derived myogenic progenitors 
are regulated by distinct gene regulatory networks where the bicoid-related Paired Like 
Homeodomain 2 (PITX2) and the T-box factor TBX1 TFs play a primary role. Independently of their 
origin, muscle differentiation of precursors depends on the activities of Muscle Regulatory Factors 
(MRFs) and their co-activators, the ubiquitous E proteins and the Myocyte Enhancer Factor 2 (MEF2) 
proteins. The fetal-specific gene expression program also involves the activity of Nuclear Factor I/X 
(NFIX). Post-natal muscle maturation is the result of several different processes including muscle 
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Figure 1. Model of skeletal muscle formation and the transcription factors (TFs) involved in the control
of the different waves of myogenesis. MYF5+ cells from the somitic dermomyotome are the first
muscle precursors that differentiate into the myocytes of the early myotome, which provides the
basic scaffold on which skeletal muscle forms in the sequential waves of myogenesis. Subsequently,
PAX3/PAX7 positive cells give rise to muscle precursors during development and post-natal muscle
growth: embryonic and fetal myoblasts give rise to embryonic and fetal myofibers, respectively.
Satellite cells (SC) appear at the end of gestation and are responsible for postnatal growth (juvenile SC)
and regeneration (adult SC). Extraocular and first branchial arch-derived myogenic progenitors are
regulated by distinct gene regulatory networks where the bicoid-related Paired Like Homeodomain
2 (PITX2) and the T-box factor TBX1 TFs play a primary role. Independently of their origin, muscle
differentiation of precursors depends on the activities of Muscle Regulatory Factors (MRFs) and
their co-activators, the ubiquitous E proteins and the Myocyte Enhancer Factor 2 (MEF2) proteins.
The fetal-specific gene expression program also involves the activity of Nuclear Factor I/X (NFIX).
Post-natal muscle maturation is the result of several different processes including muscle growth
(nuclear accretion and protein synthesis), fiber type specification induced by innervation and transition
from embryonic to adult splicing isoforms of contractile and metabolic enzymes isoforms. The main
TFs involved in the control of these processes are indicated, and the TFs that undergo alternative
splicing are underlined in bold. A detailed description of the TFs networks can be found in the text.
An indicative timing of murine development is depicted.
4. Alternative Splicing in Skeletal Muscle
4.1. Alternative Splicing
AS is a process by which exons or portions of exons or noncoding regions within a pre-mRNA
transcript are differentially joined or skipped, resulting in multiple protein isoforms being encoded
by a single gene. Different mRNA transcripts of a gene can be expressed in different tissues or
developmental stages or physiological conditions. In addition to its role in the diversification of the
proteome, AS regulates the abundance of about 35% of alternatively spliced transcripts that acquire
premature termination codons and are degraded by the nonsense-mediated mRNA decay (NMD)
pathway [99–101]. Finally, AS seems to play a role in the evolution of the protein sequences. AS
takes place through different mechanisms, including exon skipping, use of alternate 3′ and 5′ splice
donor/acceptor sites, intron retention and inclusion of mutually exclusive exons, as schematized in
Figure 2 [102]. Splicing of primary transcripts is catalyzed by the spliceosome, composed of small
nuclear RNAs and more than 200 polypeptides, which ensures accurate identification of splice sites.
Genes 2018, 9, 107 8 of 31
AS is regulated by ubiquitous and tissue specific RNA binding Proteins (RBPs) that recognize cis
regulatory elements in the pre-mRNA located within alternative exons and/or flanking introns [103].
The ubiquitously expressed serine/arginine (SR) and hnRNP proteins enhance or repress respectively
splice site recognition. Pre-mRNA splicing is often coupled with transcription due to the recruitment
of serine/arginine (SR)-proteins, well characterized regulators of splicing, to nascent pre-mRNA by the
hyperphosphorylated C-terminal domain (CTD) of the RNA polymerase II [104,105]. The coexistence
of the transcriptional machinery and the spliceosome allows transcriptional coregulators to influence
the splicing pattern of the nascent transcripts [106–108].
4.2. Alternative Splicing in Skeletal Muscle Physiology
Muscle is one of the tissues where AS is particularly important: it is believed to play a key
role in reprogramming the transcripts of contractile protein genes, metabolic enzymes and TFs,
required during the sequential waves of skeletal myogenesis in development and in post-natal life
to adapt muscular tissues to changes in metabolic and functional requirements [109,110]. Similar
to TFs, tissue-specific splicing regulators coordinate the AS patterns of several transcripts encoding
proteins that function in biologically coherent pathways. Therefore, proper control of the splicing
machinery is relevant for muscle function in mammals, as alteration of splicing pattern can lead
to major muscle and heart diseases. Global analyses of AS transitions during skeletal muscle
differentiation has allowed defining a “muscle code” that underlies muscle-specific splicing programs,
whose disruption is observed in several neuromuscular diseases [6,110,111]. A role of relevance in
controlling muscle-specific AS is played by several RBP: the Muscle-blind-like (MBNL) and CUG-BP
Elav-like family (CELF) families, whose antagonism is important to guarantee a correct skeletal
myogenesis [112–114]. Other RBPs that regulate myogenic splicing are polypyrimide tract binding
protein (PTB), RNA Binding Motif Protein 24 (RBM24) and 4 (RBM4) and RNA Binding Protein, Fox-1
Homolog (RBFOX) splicing factors [115–117].
4.3. Aberrant Alternative Splicing in Skeletal Muscle Pathologies
As discussed above, AS plays a key role in skeletal muscle development; consequently, alterations
in AS of muscle genes are often observed in neuromuscular diseases. Aberrant AS can arise from
mutations in cis-acting RNA sequences or in trans acting regulatory factors [6,7]. Mutations in cis
regulatory elements result in altered AS of a single gene and are at the basis of several diseases, for
example mutation in the 5′ splice site of the LMNA gene, encoding lamins causes the Limb Girdle
Muscular Dystrophy type 1B (LGMD1B, OMIM # 159001), and splice site mutations in the dystrophin
(DMD) gene has been observed in 20% of Duchenne Muscular Dystrophy patients (DMD, OMIM #
310200) [118] (rev in [6,7]). Reduced availability of myogenic splicing factors is observed in Myotonic
Dystrophy type 1 (DM1, OMIM # 160900) and type 2 (DM2, OMIM # 602668) and in FSHD (OMIM
# 310200). DM are autosomal dominant inherited disorders characterized by multisystem organ
involvement, including skeletal muscle, hearth and central nervous system. At the molecular level,
they are caused by the expression of expanded CUG (DM1) or CCUG (DM2) repeats in noncoding
regions of the genes encoding respectively the Myotonic Dystrophy Associated Protein Kinase (DMPK)
and Zinc Finger Protein 9 (ZNF9) respectively. These expansions act by dominant RNA gain of function,
they accumulate in intranuclear foci where MBNL1 protein is sequestered [25]. Indeed, transgenic
mice, harboring CTG repeats inserted into the skeletal α-actin 3′ UTR (HSALR), form nuclear foci
and present symptoms of DM1 such as myotonia, similar to Mbnl1 knockout (KO) mice [119,120].
Furthermore, nuclear levels of CUGBP1 is increased as a result of increased phosphorylation and
subsequent protein stabilization by Protein Kinase C [6,121–125]. These aberrant activities of splicing
regulators result in the disruption of the transition from embryonic/fetal to adult splice isoforms
of transcripts encoding proteins involved in muscle contractility, sarcomere structure and signaling,
which is incompatible with the function of the developed tissue [25]. Besides the adult form of DM1,
a congenital myotonic dystrophy (CDM) also exist where developmental RNA splicing transitions
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are disrupted and this represents the major pathogenetic mechanism [126]. FSHD is an autosomal
dominant disorder characterized by atrophy and weakness of selective muscle groups. Reduced levels
of expression of RBFOX1 and misregulated splicing of RBFOX1-dependent muscle exons have been
observed in patients affected by FSHD, as well as in a mouse model that overexpresses FRG1 (FSHD
region gene 1), a candidate gene for this disease [127–129]. Furthermore, splicing alterations have been
identified as secondary to muscle regeneration and cancer cachexia [130,131].
5. Alternative Splicing of TFs in Skeletal Muscle Physiology and Muscle Diseases
AS plays a central role in the regulation of the activity of TFs, affecting their structure in two
major ways: (i) alterations of their DNA-binding domains; or (ii) alterations of the domains involved
in the interaction with their cofactors [2]. Such changes result in modifications of DNA binding
specificity or affinity or in the switch between activator and repressor isoforms of the same TF.
AS is often coupled to other gene regulatory mechanisms, such as post-translational modifications
and protein-protein interactions, thus expanding further the repertoire of gene/protein activities
in response to developmental and environmental cues [101]. In general, variant splice forms result
in proteins with different functions. These can range from minimal changes in function to even
opposite functions. For example, some splicing isoforms of the MEF2 transcription factors differ for the
different efficiency to activate muscle-specific transcription while other isoforms function as negative
regulators of muscle transcription (see below). A fraction of the splice variants of muscle TFs regulate
oppositely the balance between proliferation and differentiation of muscle progenitors. Similarly, the
ubiquitous TF Nuclear Transcription Factor Y (NF-Y), whose activity decreases during terminal muscle
differentiation through down-regulated expression of the DNA binding subunit NF-YA [132], has been
recently shown to control proliferation and differentiation by AS of the Nf-ya gene [133]. Despite AS of
Nf-ya gene, generated by inclusion or exclusion of exon 3, does not affect the DNA binding ability of
the complex but generates two proteins, NF-YAs and NF-YAl, that differs for only 28 aa in the Q-rich
transactivation domain. The two NF-YA isoforms are able to activate different transcriptional programs
and exert opposite activities in the regulation of proliferation and differentiation of skeletal muscle
cells in cultured myoblasts [133]. Below are described the AS events of myogenic transcription factors
and what is known from literature on the involvement of their aberrant AS in muscle pathologies.
Myogenic TFs that are regulated by AS are indicated in Figure 1. Data are summarized in Table 1 and
Figure 2. The knowledge of these aberrant splicing as well as being important from a cultural point of
view can provide the necessary knowledge to develop new therapeutic strategies aimed at treating
such diseases.
5.1. Pax Family Genes
PAX transcription factors contain a highly conserved N-terminal DNA binding domain, namely
the paired domain (PD) [134]. In higher vertebrates, PAX proteins are grouped according to the
presence of an additional DNA-binding homeodomain (HD) and/or an octapeptide region, which
can allow the interaction with other transcriptional regulators [135]. A transactivation domain (TA) is
located at the C-terminus of all PAX proteins.
All Pax genes, except for Pax4 and Pax9, produce alternative splice transcripts, which encode for
PAX proteins that differ in structure and DNA binding activity. Pax3 and Pax7 genes belong to group
III and share similar structure. They are both subjected to alternative splicing in the N-terminal PD,
which gives rise to isoforms differently expressed throughout development [136–138]. Indeed, these
isoforms differentially regulate gene transcription through their diverse DNA-binding ability [139,140].
The N-terminal alternative splicing of Pax3 occurs at the junction between intron 2 and exon 3 and
produces two PAX3 proteins which differ for the inclusion or not of a glutamine residue (PAX3/Q+ and
PAX3/Q-). The occurrence ratio between the two splice transcripts is about 2:1 in favor of Pax3/Q+.
Murine PAX3/Q- variant seems to have stronger binding affinity and transactivation activity to class I
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sites, those DNA elements interacting with both C-terminal and N-terminal subdomains of PAX PD
domain [138]. The two variants are expressed also in zebrafish, with a Q+/Q− ratio of 3:2 [141].
Q+/Q− splice events occurs also in murine Pax7 pre-mRNAs, which additionally undergo
a second splicing event at the intron 3/exon 4 junction that results in inclusion or exclusion of a
glycine/leucine (+/−GL) dipeptide in C-terminal PD subdomain. In zebrafish, only the PAX7/Q+
variant is present among the multiple isoforms identified for Pax7. The lack of this isoform reduces the
range of potential target sites identified for the murine Pax7/Q− [138,141,142].
The distribution and expression of N-terminal variants have been studied together with
PAX3/PAX7-FKHR fusions in rhabdomyosarcoma (RMS) [139].
The C-terminal region of PAX proteins has a role in gene transactivation through protein-protein
interactions, but could also affect DNA binding activities of the paired domain [142,143]. In addition
to the N-terminus, the C-terminus can be differently spliced, predominantly by splicing the exon
8 [144–146].
The predominant PAX3 C-terminal isoforms, PAX3c and PAX3d, have been well characterized in
human melanocytes [147] and less extensively in mouse muscle cells [146]. Pax3c transcript retains
intron 8 and translation proceeds for five codons into intron 8 before termination. Differently, Pax3d
transcript lacks intron 8 and translation continues from exon 8 to 9. The encoded protein does lacks a
portion of the TA domain Pax3 alternative C-terminal transcripts show different expression during
myogenesis in committed and uncommitted precursor cells [146]. In particular, Pax3c is not expressed
in undifferentiated immortalized mouse myoblasts and uncommitted mesenchymal cells (MSCs) but
its transcriptional levels rise following differentiation. Differently, Pax3d transcript is marginally
increased in differentiated cells compared to undifferentiated ones. These results prompted Ziman
and coworkers to propose that Pax3c can be necessary for terminal myogenic differentiation while
Pax3d may have a role in maintenance and/or proliferation of undifferentiated cells [146]. Two other
Pax3 C-terminal isoforms have been described: Pax3a and Pax3b transcripts are prematurely truncated
in intron 4 and, consequently, lack the homeodomain (HD) and the C-terminal TA domain. Pax3b
expression has been found in most tissues, while Pax3a only in skeletal muscle, cerebellum and
esophagus [148].
PAX7 C-terminal splicing is controlled by differential transcriptional termination in the beginning
of intron 8 or in exon 9: through different RNA cleavage-polyadenylation and splicing, two alternative
PAX7 proteins are expressed, PAX7A and B [149]. Pax7A and Pax7B transcripts are present in
both undifferentiated and differentiated myoblasts, while they are expressed in MSCs only after
differentiation, suggesting a role in myogenic commitment [146]. A protein isoform similar to PAX7A
with the alternative C-terminal end was previously described in zebrafish as transcript Pax7d [141].
In addition, in chicken, an alternative Pax7 C-terminal splicing isoform has been identified
(Pax7-2) in myoblasts. This mRNA variant encodes for a 22-amino acid-deleted protein, localized
within myoblasts nuclei, which seems to be important in gene transactivation, at least in in vitro
assay [150].
In RMS, Pax3 and Pax7 are normally expressed in the embryonal subtype (ERMS). Differently,
chromosomal translocations occurring in the alveolar subtype (ARMS) juxtapose Pax3 or Pax7 with
forkhead transcription factor gene (FKHR), generating PAX3-FKHR or PAX7-FKHR fusion proteins.
The fusion of PAX3/7 N-te DNA binding domain with the C-terminal transactivation domain of FKHR
strongly enhances PAX transcriptional activity, which results in deregulated growth and differentiation
of myogenic lineage. Multiple isoforms of wild-type PAX3/7 and PAX3-FKHR/PAX7-FKHR with
different transcriptional properties are expressed in ERMS and ARMS, respectively, as the consequence
of alternative splicing events in the PD region [139].
5.2. Myogenic Determination Factor Gene
The teleost Takifugu rubripes has been used as a model to study the molecular basis of myogenesis.
The ortholog of MyoD1 in this species (TMyoD1) has a genomic organization similar to zebrafish
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and human MyoD. Three splice variants of TMyoD1, α, β, and γ, have been identified and their
role have been investigated in embryonic development and in fast and slow myotomal muscle [151].
The splice transcripts TmyoD1-β and TmyoD1-γ differ from TmyoD1-α because of an alternative 3′
splice site and the retention of intron I, respectively. Specifically, TmyoD1-β is characterized by a 78 bp
insertion encoding for 26 residues, which results from partial retention of intron II. The putative protein
encoded by TmyoD1-α is composed of 281 residues that correspond to MyoD1 from other vertebrates.
TMyoD1-α, characterized by a 28-residue serine-rich region with multiple phosphorylation sites, seems
to be transcriptionally expressed only in percomorph teleosts. The expression of α and β isoforms is
presumably associated to growth stages and changes with body size. The TmyoD1-γ isoform, which
retains intron I, is not translated and seems to have a role in the regulation of TmyoD1 expression by
nonsense-mediated decay.
In the ascidian Ciona intestinalis, two differentially regulated MyoD transcripts (CiMDFa and
CiMDFb) have been described. While in eggs and early cleavage stage embryos, CiMDFs are absent,
the transcripts are expressed during embryogenesis and in adult body-wall muscle [152]. CiMDFb and
CiMDFa mRNAs initiate at the same transcription start site, but the CiMDFb open reading frame is
extended compared to CiMDFa, originating a specific 3′-untranslated. This extension is translated into
68 amino acids that include the Domain III, a domain conserved among vertebrate MyoD family genes
and involved in the effector functions of MyoD family proteins [153,154].
In mammals, no different splice variants have been ever described. Anyway, it has been reported
that the processing of MyoD pre-mRNA to mature mRNA is regulated in muscle cells through
Mettl3-induced m6A modification [155]. Methyltransferase like 3 (Mettl3) is indeed able to induce
N6-methyladenosine (m6A) modifications in RNAs, affecting splicing, stabilization/destabilization,
nuclear export and translation efficiency of RNA molecules [156–158]. Specifically, Kudou et al.
showed that Mettl3 knockdown decreased the levels of processed MyoD mRNA, without affecting
the unprocessed one. Moreover, they showed that MyoD mRNA levels are maintained during cell
proliferation through Mettl3-induced m6A modification at 5′ UTR [155].
5.3. Nuclear Factor 1/X Gene
NFIX transcription factor belongs to the Nuclear Factor I (NFI) family and has a key function
in muscle development. NFI proteins share a conserved DNA-binding and dimerization domain at
the N-terminus and a transcriptional activation/repression domain at the C-terminus. They all have
multiple splice variants. In the mouse, the longest Nfix3 isoform is considered the canonical transcript.
Alternative splicing is observed by exon skipping of exon7 and exon9, that gives rise to product
variants in the C-terminus [159]. Specifically, Nfix1, identified also in human, chicken, hamster and
rabbit, lacks exon9, while Nfix2 lacks both exon7 and exon9. Exon 8–10 joining leads to an alternative
protein sequence encoded by the last exon. The expression of the three spliced transcripts, Nfix1, Nfix2
and Nfix3, was identified in different tissues. In mouse fetal myoblasts, Nfix1 and 2 are the predominant
expressed isoforms, with Nfix2 being a well demonstrated key regulator of the transcriptional switch
of many embryonic/fetal muscle genes [73].
Increased Nfix exon 7 inclusion was observed in patients affected by DM2, caused by the expansion
of the (CCTG)n repetition in the first intron of the CNBP gene [160]. The potential mechanism through
which this splice variants can contribute to DM2 pathogenesis has not been yet elucidated. Perturbed
Nfix splicing has been also observed in DM1 mouse models and human DM1 patients. Unfortunately,
the lack of a wide number of patients did not allow rigorously determining the value of such aberrant
splicing [123].
Nfix point mutations have been reported to cause Marshall-Smith syndrome (MSS, OMIM #
602535), characterized by failure to thrive and accelerated skeletal maturation but also skeletal
hypotonia and muscle weakness. It has been proposed that mutations on the different Nfix isoforms
may have variable phenotypic effects. For example, the c.1496delT mutation identified in one MSS
patient alters the stop codon of the short isoforms, which therefore have additional 20 amino acids
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at the C-terminus. Differently, the mutation in the long isoforms, generated by exon 9 inclusion,
introduces a frameshift that encodes for a long proline-rich transactivation C-terminal domain.
Finally, among mutations identified in MSS patients, a variant affecting the donor-splice site of
intron 6 has been described that leads to a partial inclusion of intron 6, triggering similar consequence
to a frameshift mutation [161].
5.4. Myocyte Enhancer Factor-2 Family Genes
The MEF2 family includes four members in mammals: MEF2A-D share an N-terminal DNA
binding region composed of a MADS box (MCM1, agamous, deficient, serum response factor) (57 aa)
and MEF2 (29 aa) domains, that mediate the binding to the CTA(T/A)4TAG DNA sequence (MEF2
site), two central transcription activating domains (TAD1 and TAD2) and a C-terminal nuclear
localization sequence [64]. In post-natal myogenesis, MEF2 proteins regulate gene expression programs
in response to many extracellular cues, therefore their activities are tightly regulated by multiple
mechanisms, among them AS occupies a relevant role. Mef2 transcripts undergo extensive AS in
different species, generating RNAs encoding splice variants, for most of them it has been shown that
they exhibit differential activities in cultured cells and in vivo [74,162–171]. AS of MEF2 proteins plays
a role in skeletal muscle development [72,162,169,172] as well as in adult myogenesis [74,163,164].
In addition, MEF2 splicing patterns are altered in most neuromuscular dystrophies, cancer cachexia and
rhabdomyosarcoma cell lines [130,164,173]. In mammals, Mef2 transcripts undergo three different AS.
A mutually exclusive AS occurs between exons α1 and α2, located in the region immediately adjacent
to the MEF2 domain in MEF2A, -C and -D [174]. In the central TAD2 region, a skipping-type alternative
splice can include exon β; in addition, exclusively for Mef2c transcripts, a splice involving alternative 3′
splice site selection occurs in the γ region near the C-terminus [167,168]. Inclusion of β exon has been
observed in Mef2 transcripts expressed in skeletal muscle and brain and in differentiating cultured
muscle cells; the encoded MEF2 variants are characterized by a strong transcriptional activity [167,174].
A decrease in the expression of Mef2d transcripts including exon β has been observed in DM1 muscle
tissues [175]. The γ region of mouse Mef2c functions as a transrepressor of MEF2C transcriptional
activity by a mechanism associated with the phosphoserine-dependent sumoylation of a Lys residue
located in the domain [176–180]. Coherently with these observations, Mef2c transcripts depleted of the
γ region are abundant in differentiating murine C2C12 cells, when the muscle-specific MEF2-dependent
transcription must be activated [168]. A recent work has demonstrated the enormous regulatory role
played by alternative inclusion of α1/α2 exons in Mef2 transcripts. The group of Dilworth has shown
that alternative inclusion of α exons in Mef2d transcripts gives rise to a ubiquitous (MEF2Dα1) or a
muscle-specific (MEF2Dα2) isoform, that behave as transcriptional repressor or activator of muscle
differentiation, respectively. MEF2Dα1 is negatively regulated by phosphorylation catalyzed by protein
kinase A (PKA) on a serine residue located in the α1 exon. This modification allows its interaction with
the HDAC deacetylase complexes. On the contrary, exon swapping generates the MEF2Dα2 isoform
that is not susceptible to the PKA-dependent inhibition and can recruit to muscle genes the coactivator
ASH22L methyltransferase complex, a known coactivator of MEF2 proteins [181,182]. This exons
switch plays a key role in temporally regulating skeletal muscle terminal differentiation both in vitro
and in vivo in mouse models of muscle regeneration [163]. Mutually exclusive AS of exons α1/α2
plays also a primary role in regulating the transcriptional activity of MEF2C. Analogously to Mef2d,
inclusion of α2 exon in Mef2c transcripts is important to guarantee efficient myogenic differentiation
in vivo, in cultured muscle cell lines and primary myoblasts [74,164]. We found a serine residue in the
peptide encoded by α1 exon whose phosphorylation mediates the interaction with the peptidyl prolyl
cis/trans isomerase PIN1, a repressor of muscle differentiation. In its phosphorylated form MEF2Cα1
regulates genes involved in cell cycle progression [166,183,184]. We also found that dephosphorylated
MEF2Cα1 has a pro-hypertrophic activity in vivo in adult skeletal muscle, by activating the expression
of Insulin like Growth Factor 1 (Igf1) gene [74]. A similar function in activating cardiac hypertrophy gene
expression has been demonstrated for MEF2Cα1 in cardiac muscle [165]. Aberrant splicing of Mef2a
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and Mef2c transcripts has been reported in several neuromuscular diseases, including DM1 and DM2,
where a higher inclusion of α1 exon has been observed [173]. Increased inclusion of the α1 exon in
MEF2C transcripts was observed in cell lines of rhabdomyosarcoma, a pediatric tumor characterized
by cells that are positive for markers of myoblasts (MYOD and myogenin) and differentiated skeletal
muscle (Desmin and Myosin Heavy Chain MHC) but they continue to replicate. MEF2Cα1 was
shown to contribute to the ineffective muscle terminal differentiation observed [164,185]. Furthermore,
an increase of the α1/α2 ratio in Mef2 transcripts has been observed in failing human and mouse
hearts [165]. Splicing of Mef2 transcripts is regulated by several RBPs, MBLN3 and nPTB can repress
inclusion of β exon [175,186]. RBFOX has been shown to promote the inclusion of muscle specific α2
exon and of the acidic β exon in Mef2d transcripts in skeletal muscle cells and the inclusion of Mef2 α2
exon in cardiac muscle [165,187,188].
5.5. Ubiquitous bHLH Proteins Class I
Ubiquitous bHLH Class I subfamily consists of E2A/TCF3, HEB/TCF12 and E2-2/TCF4 proteins.
Dimerization occurs through the C-terminal HLH motif, which is also required for DNA binding,
together with the preceding stretch of basic amino acids.
Mammalian E12 and E47 proteins arise by mutually exclusive inclusion of exon 17 or 18 of the
E2A/TCF3 gene and differ in the exon encoding the bHLH region [189]. Both the isoforms dimerize
with MYOD and other myogenic bHLH TFs [190]. In RMS, an in-frame splice variant of E2A (E2A-2/5),
that removes exons 3 and 4 encoding for part of the activation domain 1 (AD1) region, was identified.
In vitro data suggest that E2A-2/5 variant interferes with the function of the full-length E2A proteins
by incorporating them in a multiprotein complex [191]. Both E12-2/5 and E47-2/5 transcripts have
been detected in RMS cells [191]. Yang et al. hypothesized that these alternative spliced proteins could
disrupt the balanced equilibrium between bHLH factors that dimerize with E-proteins, and lead to
the formation of repressive rather than active complexes, that prevent the full activation of MYOD,
necessary for terminal differentiation [191].
As the HEB/TCF12 gene concerns, two alternative spliced isoforms exist, namely HEBα and
HEBβ. The HEBβ isoform arises from alternative inclusion of a 72-bp sequence (exon 15), which
encodes for a 24-amino-acid ankyrin-like motif [192]. The two isoforms exhibit different DNA binding
affinity as well as homo- and heterodimerization properties. HEBβ levels increase during myogenic
differentiation, while HEBα is expressed in both proliferating and differentiating myoblasts. Loss
of HEBβ expression reduces the transcriptional activity of MYOD, impairs myogenin expression and
differentiation into multinucleate myotubes [193].
Initially, the E2-2/TCF4 gene was found to encode for three amino-terminally distinct proteins,
namely TCF4-A, TCF4-B and TCF4-D, which share the C-terminal bHLH domain and a transcription
activation domain (AD2) [194,195]. Compared to TCF4-B and TCF4D, TCF4-A does not contain the
exons encoding the nuclear localization signal (NLS). TCF4-B has an additional transcription activation
domain in its N-terminus (AD1). Later studies showed that human TCF4 gene transcription could use
alternative 5’ exons, originating a multitude of TCF4 protein isoforms (TCF4-A–TCF4-R) that have
different cellular localization and transactivation potential [195]. Moreover, alternative splicing of
TCF4 gene generate +/− isoforms, which result from alternative splice donor site selection at exon
18, that differ by the presence or absence of four amino acids (RSRS). Transcripts of -/+ variants are
expressed in a variety of tissues, muscles included [195].
Finally, full-length/∆ isoforms can be produced by AS that include or not the NLS-containing
region. In vitro transactivation assay showed the isoforms containing the full length AD1 have stronger
transactivation ability, while no significant correlations exist between activation of gene transcription
and the presence of the four extra amino acids in the + isoforms.
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5.6. Inhibitor of DNA Binding (ID) Genes
Another class of HLH proteins is represented by Inhibitor of DNA binding (ID) proteins, which,
in opposition to E-proteins, work as transcriptional repressors by forming antagonistic dimers with
E-proteins [196]. Indeed, the members of the ID family proteins, ID1–ID4 in mammalian cells, have
the HLH domains but lack the basic DNA binding domain [197]. ID proteins are therefore considered
to be dominant negative HLH transcription factors, that prevent skeletal muscle differentiation by
blocking the activity of MYOD and other myogenic bHLH proteins. Consistently, ID levels are rapidly
down-regulated during terminal myoblast differentiation and their forced expression inhibits cell
differentiation [198].
The Id-1 gene is regulated through alternative splicing: two different splice transcripts, Id-1A and
Id-1B, have been described. In humans, Id-1A and Id-1B transcripts encode for 155 and 149 amino
acids proteins, respectively; differently, in mice, ID-1A and ID-1B proteins contain 148 and 168 amino
acids, respectively [199]. The C-terminal sequence is different between these two isoforms and has
been associated with their ability to interact with other TFs. While ID-1A inhibits the formation of
E12/MYOD heterodimers, ID-1B prevents the assembly of E12/E12 homodimers. Similarly, Id-3 is
expressed in proliferating skeletal muscle cells and is transcribed into two alternative splice transcripts,
Id-3 and Id-3L, generated by alternative splicing that retains or not the first intron. The last one encodes
for a protein of 160 amino acids compared with 119 amino acids of the canonical isoform. The two
spliced variants use alternate ORF in the second exon region and therefore have different C-terminal
region, with ID-3L being longer than ID-3 [200]. The two isoforms are functionally different, with
ID-3L being unable to abrogate E47 binding to the consensus E-box site in vitro [200].
Table 1. Alternative Splicing (AS) of myogenic Transcription Factors: the table provides splicing
mechanisms, species and references for the described transcription factors.
Family genes Transcriptionfactor Splicing isoforms Spliced region/domain Species References
Pax
PAX3
Pax3Q+/Q−
Alternative splicing
intron2/exon3
(N-terminus, linker region of
the PD)
Zebrafish
Mouse
Human
[136–141]
Pax3A/B
Termination at intron 4
(lack of HD and TA domains)
Mouse
Human [148]
Pax3C/Pax3D Alternative splicing of exon 8(C-terminus) Mouse
Human
[146,149]
PAX7
Pax7Q+/Q−
Alternative splicing
intron2/exon3
(N-terminus, linker region of
the PD)
Mouse
Human
[146,147]
Pax7GL+/GL−
Alternative splice at intron
3/exon 4 boundary
(C-terminus PD subdomain)
Mouse
Human [137,139]
Pax7A
Pax7B
Termination at intron 8
Termination at exon9
(C-terminus)
Mouse
Human
[146,147]
Pax7-2 Alternative splicing of exon8(C-terminus) Chicken [150]
bHLH
(Class I and II)
MYOD
TMyoD1α/β/γ Alternative retention of intronI and partial intron II
Takifugu
rupripes [151]
CiMDFa/b Extension to 3’UTR(Domain III)
Ciona
intestinalis [152]
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Table 1. Cont.
Family genes Transcriptionfactor Splicing isoforms Spliced region/domain Species References
E2A/TCF3
E12/E47
Alternative inclusion of exon
15 (bHLH encoding exons
- C-terminus) Mouse
Human
[191–193]
E2A-2/5
Exclusion of
exons 3 and 4
(part of N-terminal AD1)
HEB Hebα/β
Inclusion of alternate exon
(24-amino-acid ankyrin-like
motif)
Rat
Mouse
Human
[194,195]
E2-2/TCF4
Tcf4A-R
Mutually exclusive 5’ exons
(N-terminus)
Tcf4+/−
Alternative splice donor site
selection at exon 18
(C-terminus)
Mouse
Human [196,197]
FL/∆Tcf4
Exclusion/inclusion
exons 8/9
(N-terminal NLS)
HLH
(Class V)
ID1 Id1A/B Inclusion/exclusion intron I(C-terminus)
Rat
Mouse
Human
[199]
ID3 Id3/3L Inclusion/exclusion intron I(C-terminus)
Rat
Mouse
Human
[200]
Nfi NFIX
m/h/ha/ch/r
Nfix1
m Nfix2
m Nfix3
Exon9 splicing
Exon 7 and 9 splicing
Exon 7 and 9 retention
(C-terminus)
Chicken
Hamster
Mouse
Rat
Human
[73,159]
Mef MEF2A/C/D
Mef2aα1/α2
Mef2cα1/α2
Mef2dα1/α2
Mef2aβ
Mef2cβ
Mef2dβ
Mef2cβ/γ
Alternative splicing
exon α1/α2
Exclusion/inclusion
exon β
Exclusion/inclusion
exon β or γ region
Mouse
Human
[74,163–166,173,
174,182]
[167,175]
[168,176–179]
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6. Discussion 
In this review, we have summarized the data in literature describing how AS modulates the 
activities of TFs in skeletal myogenesis and in neuromuscular diseases. We found that several TFs 
involved in myogenic transcription are regulated by AS and misregulation of their AS patterns is 
observed in neuromuscular pathologies, suggesting that their altered activities in these pathologies 
could play an important pathogenic role. AS is widespread in eukaryotes, indeed genome-wide 
studies demonstrated that greater than 90% of mammalian multi-exon genes undergo AS [201,202]. 
Among genes subjected to AS, a category particularly represented is that of TFs both in human and 
in mouse [3,4]. Coherently with these observations, our scan of what has been published in the 
literature has demonstrated that most TFs involved in the regulation of muscle gene expression are 
regulated by AS. It is therefore surprising that the transcripts of the MRFs are not subjected to AS, 
except in lower organisms where one single MRF is present in the genome [151,152]. It has been 
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6. Discussion
In this review, we have summarized the data in literature describing how AS modulates the
activities of TFs in skeletal myogenesis and in neuromuscular diseases. We found that several TFs
involved in myogenic transcription are regulated by AS and misregulation of their AS patterns is
observed in neuromuscular pathologies, suggesting that their altered activities in these pathologies
could play an important pathogenic role. AS is widespread in eukaryotes, indeed genome-wide
studies demonstrated that greater than 90% of mammalian multi-exon genes undergo AS [201,202].
Among g nes subjected to AS, a category particularly represented is that of TFs both in human
and in mouse [3,4]. Coherently with these obse vations, ur scan of what has be n published in
th literature has demonstrated that most TFs involv d in the r ulation of muscle gene xpression
are regulated by AS. It is therefore surprising that the transcripts of the MRFs are not subjected to
AS, except in lower organisms where one single MRF is present in the genome [151,152]. It has
been proposed that AS is less represented in genes that are part of multi-members families derived
from gene duplication, such it might be the case of the MRFs family of TFs [203,204]. However, this
hypothesis is controversial [205] and it would not apply to the MEF2 family of proteins that also
comprises four members whose transcripts undergo very complex AS mechanisms, as reviewed
in [64]. Proteins encoded by transcripts th t are subject to AS have a wider vulnerability to mutations
th t could alter their function, g ven that the correct splicing pattern is the result of a complex
splicing regulatory network that involve cis-acting RNA sequ nc s and RNA binding proteins that are
themselves regulated by AS and post-translational modifications. In addition to that, splicing is often
a co-transcriptional process whose final pattern is modulated by the rate of transcriptional elongation
by RNA polymerase II and by transcriptional co-regulators. Consequently, correct splice site selection
requires the cross talk of multiple regulatory complexes.
MRFs proteins are master regulators of the fate of multipotent cells, whose altered function would
have dramatic outcomes on the development of the organism. Therefore, one could reason that the
absence of AS of their transcripts could have a protective role against the dramatic consequences of
its alt ation.
On the other hand, AS regards extensively transcripts encoding proteins involved in the
mechanisms of remodeling and muscle adaptation to physical exercise or nutritional conditions,
such as NFIX and MEF2, conferring to these TFs a greater and more articulated ability to respond to
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the different stimuli to which the muscle is subjected. We should not forget that also transcriptional
co-activators play a key role in the establishment of correct muscle transcriptional programs. Some
of these are also subjected to AS. An example is represented by the PGC-1α protein, which has
been first identified as a coactivator of the nuclear receptor PPARγ in brown adipose tissue where it
controls adipocyte differentiation, and subsequently it has been shown to co-activate a number of TFs
forming transcriptional complexes that are involved in the adaptation of tissues to nutrient and energy
needs [206–208]. In skeletal muscle PGC-1α regulates the molecular and biochemical events that
underlie muscle remodeling in response to physical exercise, by inducing mitochondrial biogenesis,
slow fiber conversion, stimulation of fatty acid oxidation and angiogenesis, increased levels of PGC-1α
have a protective role against atrophy, obesity, and diabetes [209–211]. Use of alternative promoters
joined to AS of the transcripts gives rise to multiple PGC-1α protein variants that are structurally and
functionally distinguishable. Interestingly, the arginine–serine-rich (RS) domain and the C-terminal
RNA recognition motif (RRM) of the protein [212], confer to the full length PGC-1α1 protein the
ability to modulate AS of the nascent transcripts of transcriptional target genes [213]. AS gives rise
to PGC-1α variants that are characterized by differential stabilities and specific effects over target
gene expression and splicing. As reviewed in detail in [6–9], several neuromuscular disorders are
characterized by defects in AS and much has been discovered about altered splicing of the transcripts
encoding contractile or calcium handling proteins and their correlation to the clinical aspects of the
diseases. For example, in DM, misregulated splicing of the muscle-specific chloride channel (CLNC1)
can cause myotonia while that of insulin receptor (INSR) correlates with insulin resistance [214].
In FSHD, muscle impairment in both humans and mouse models has been correlated to aberrant
splicing of MTMR1, TNNT3 and CAPN3 [127–129]. However, some data in the literature suggest that
aberrant AS of transcripts encoding proteins involved in muscle homeostasis and function might not
be the only driving mechanism, starting from the observation that DM-specific altered splicing patterns
concerns a relatively low number of transcripts, being most of them secondary to muscle regeneration
induced by muscle damage [131,215]. Coherently with this hypothesis, recent research work described
the analysis of the gene expression pattern in skeletal muscles of two recognized animal models of
DM1, the HSALR and Mbnl1 KO mice. These models show that the molecular defects underlying the
pathology not only results in AS defects but also in alterations of the transcriptome, that can be only
partially ascribed to changes in muscle activity or to muscle damage, as evidenced by an only partial
overlap with the transcriptome changes observed in Clcn1 KO mice, exhibiting myotomia, or in mdx
mice, lacking dystrophin, a model of muscular dystrophy where muscle regeneration is continuously
active. Similarly, in a zebrafish model of DM1, obtained by injecting embryos with mRNA containing
the CUG repeats, several genes involved in muscle development are also abnormally regulated [216].
To explain changes of gene expression it has been proposed that TFs, like SP1, might be “leached” from
chromatin by mutant DMPK transcripts [217]. Such mechanism cannot however explain the changes
in gene expression that are observed in the mouse model of DM1 represented by the loss of Mbln1.
Besides alteration of AS, profound misregulation of gene expression was also described in FSHD [218].
It is conceivable that in neuromuscular pathologies characterized by altered AS, aberrant splicing of
the transcripts encoding TFs might play a role in the change in gene expression observed in these
pathologies and thus contributing to the muscular defects. However, despite these preliminary data,
very little is known about the causative role played by aberrant AS of TFs in these pathologies. It has
been widely reported that in DM1 and 2 the splicing of transcripts encoding transcription factors such
as NFIX and MEF2 are altered, in addition their splicing patterns is also altered in a mouse model
of FSHD [129,173,215,219]. Interestingly, these proteins are involved in the transcription of genes
important in fiber type specification in the transition from embryonic to more adult gene expression
programs. These two categories of genes are actually those for which an alteration has been detected in
these neuromuscular pathologies. This also reinforces the hypothesis that the altered TFs splicing may
be important as a causative element of these pathologies. Consistently, a correlation between splicing
outcome of transcripts encoding NFIX and DM severity exists, indicating the potential important role
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played by abnormal splice variants of TFs in the pathogenic mechanism of DM [219]. It should also be
noted that DM and FHSD pathologies are characterized by muscle atrophy. Muscle mass is regulated
by various TFs whose AS has an important impact on their activities. Specific MEF2C and PGC-1α
splicing variants are in fact able to activate the expression of IGF1 [74,220], hence it is conceivable that
alterations of their splicing patterns could contribute to this aspect of the pathology, an hypothesis that
is also reinforced by the observation that cardiac hypertrophy following heart failure has been related
to alterations of the splicing pattern of MEF2C transcripts in the heart [165].
Several therapeutic strategies have been developed to treat altered splicing in neuromuscular
diseases, based on the use of Antisense Oligonucleotides (ASOs) or small molecules that can modify
and eventually correct aberrant splicing, as reviewed in [8,9,221]. ASOs can recognize specific
regulatory sequences in the pre-mRNA and influence the splicing pattern or to modulate the stability
of the transcripts. For example, Eteplirsen (Sarepta Therapeutics), a modified ASO, was the first
splicing-based approach approved as treatment for DMD patients. It induces skipping of exon
51, thus restoring the open reading frame and leading to the expression of a partially deleted but
functionally active DMD protein. Other ASOs induce skipping of exons containing mutations. ASOs
that induce the degradation of mutant DMPK transcripts in DM patients are currently in phase II
clinical trials [222]. High-throughput screens allowed to identify small molecules that regulate the
activity of RBPs by binding directly to them or by competing with RBPs for the binding to mutated
RNA sequences. For example, the antifungal pentamidine, is able to displace MBNL from CUG
repeats [223]. The recent development of the CRISPR/Cas9 gene-editing system has allowed the
long-term correction of splicing in animal models of DMD or in cells from DM1 patients, proving a
promising approach for the treatment of human diseases [224–228].
Similar approaches might be developed to rectify aberrant splicing of TFs in the same diseases to
correct so far potentially unexplored aspects of neuromuscular pathologies.
7. Conclusions and Future Directions
In summary, the results of our studies suggest that aberrant AS of genes encoding TFs may have
a role in human RNA muscular diseases. However, there are many gaps on this subject that need to be
filled in the future to evaluate the validity of this hypothesis. As a starting point it would be important
to get a more detailed picture of the splicing profiles of TFs genes in these pathologies and to clarify
whether the splice variants regulate specific muscle gene programs. Indeed, although in many cases
the consequences of AS on the biochemical function of TFs have been demonstrated in cultured cells,
their biological function in vivo is still largely obscure. Future studies are required to understand the
contribution of aberrant AS of TFs genes to the degree of pathology in RNA muscular diseases, in order
to evaluate if correcting it has a therapeutic value. Furthermore, slow muscle enrichment and muscle
growth, two processes that are protective in many muscle diseases are controlled by specific splice
variants of TFs. Therefore, regardless of whether the aberrant splicing of TFs has a causative role in
neuromuscular diseases, modulation of their splicing might be a convenient strategy to ameliorate the
disease processes anyway. Furthermore, in order to develop specific splicing-correcting compounds,
it will be necessary to get more insights about the cis-acting elements and the RBPs involved in the
regulation of AS of TFs genes.
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